Podcasts about Early Stage

Dr. Neil Adshead shares insights on how he evaluates early-stage junior mining stocks in this MSE episode. Listen to this wide-ranging conversation on what separates good exploration geologists from great ones, how prospect generators navigate a shift toward drilling their own projects, what makes a JV deal structure investor-friendly, and how Neil evaluates jurisdictions like Nevada, James Bay, and the Golden Triangle. Dr. Adshead also shares his views on billion-dollar capex copper projects, the role of infrastructure in project economics, and the portfolio discipline that has shaped his 20+ years on the buy side. Neil Adshead is an economic geologist, who incorporates his extensive theoretical and practical experience in mineral deposit geology, mineral exploration and mining into investment-related decision-making. After earning a Ph.D. in Economic Geology in 1995, he spent ten years working for Placer Dome subsidiaries – at the time, one of the largest mining companies in the world – in Canada, Australia, and Papua New Guinea. For the seven-plus years sandwiched between Placer Dome and Sprott, Neil worked as the Vancouver-based senior mining-exploration analyst for a San Francisco-based investment firm. Currently, he is a consulting geologist to the Commodity Discovery Fund. 00:00 Intro 00:44 Great Exploration Geologists 02:20 Analyst Versus Geologist 04:26 Traits of Top Analysts 06:58 Neil's Career Shift 09:27 Beyond Geology Business 11:02 Marketing Moves Shares 14:49 Prospect Generator Pivots 18:45 Trust Communication Use 21:14 JV Deal Structure Keys 24:41 Jurisdiction Prospectivity Nevada 27:32 Unorthodox Exploration Bets 27:44 James Bay Upside 28:49 Golden Triangle Potential 30:07 BC Politics Reality Check 32:31 Funding Billion Capex 36:06 Marginal Copper M&A 40:29 Infrastructure Matters 44:51 Conviction and Doubt 46:33 Position Sizing Discipline 48:42 Patience After Big Wins Sign up for our free newsletter and receive interview transcripts, stock profiles and investment ideas: http://eepurl.com/cHxJ39 Mining Stock Education (MSE) offers informational content based on available data but it does not constitute investment, tax, or legal advice. It may not be appropriate for all situations or objectives. Readers and listeners should seek professional advice, make independent investigations and assessments before investing. MSE does not guarantee the accuracy or completeness of its content and should not be solely relied upon for investment decisions. MSE and its owner may hold financial interests in the companies discussed and can trade such securities without notice. If you buy stock in a company featured on MSE, for your own protection, you should assume that it is MSE's owner personally selling you that stock. MSE is biased towards its advertising sponsors which make this platform possible. MSE is not liable for representations, warranties, or omissions in its content. By accessing MSE content, users agree that MSE and its affiliates bear no liability related to the information provided or the investment decisions you make. Full disclaimer: https://www.miningstockeducation.com/disclaimer/

The latest episode of Taste Radio's Elevator Talk spotlights emerging leaders from Gold Crush Cocktails, Roadie Brew, Ample Hydration, Pesche and Gingerbug, who introduce their brands, share recent company updates, and highlight key milestones. This week's special co-host is Dayton Miller, a managing partner with venture capital firm BFG Partners. Dayton brings insightful questions, thoughtful feedback, and a strategic perspective to the conversation alongside regular host Ray Latif, editor and producer of Taste Radio. Early-stage food and beverage entrepreneurs are invited to apply for future episodes of Elevator Talk. Participation is free, interviews are conducted remotely, and the series offers a unique opportunity to pitch your product, share company news, and get candid feedback from experienced industry leaders. Apply now to be featured in an upcoming episode.

Investigators zeroed in on a white Hyundai Elantra after reviewing surveillance footage from the neighborhood around the King Road residence, where Madison Mogen, Kaylee Goncalves, Xana Kernodle and Ethan Chapin were killed. Cameras captured a light-colored sedan repeatedly traveling through the area during the early morning hours of November 13, 2022, including several passes near the house before the killings and a rapid departure afterward. Investigators initially believed the vehicle was a 2011–2013 Hyundai Elantra, then expanded the possible model years as the analysis continued. Police agencies were asked to search registration records and locate matching vehicles, turning the unidentified Elantra into one of the investigation's most important leads.That search eventually pointed investigators toward Bryan Kohberger, who owned a white 2015 Hyundai Elantra and was living in Pullman, Washington, only a short drive from Moscow. Washington State University police identified Kohberger's vehicle after searching university registration information, and an officer subsequently located it near his apartment. Investigators then connected Kohberger to the broader evidence trail, including cellphone records, surveillance footage and ultimately DNA evidence, while tracking his movements as he drove the Elantra across the country to Pennsylvania with his father in December 2022. The car did not by itself establish that Kohberger committed the murders, but it gave investigators a concrete suspect to scrutinize and became one of the critical links that helped move the investigation from an unknown vehicle circling King Road to Kohberger's arrest in Pennsylvania.to contact me:bobbycapucci@protonmail.com

This week on Swimming with Allocators, Earnest and Alexa welcome Kelli Fontaine of Cendana Capital, as she traces her path from journalism to data-driven venture investing and explains how her obsession with finding the truth shapes her work as an LP. She breaks down how Cendana builds and uses its data systems, why early-stage power laws and portfolio construction matter more than headline TVPIs, and how she balances hard data with judgment about GPs. Kelli challenges the idea that pre-seed always outperforms seed, shares why fund I and II managers are uniquely compelling, and explores trends like concentrated portfolios, deep tech, defense tech, AI-native founders, and secondaries. Also, Sidley emerging companies lawyer Michael Podolny explains that rapid growth and complexity in AI-driven startups are driving demand for globally sophisticated legal advice from day one, with a particular focus on repeat founders, control, and tax optimization through QSBS planning. Highlights from this week's conversation include: Kelli's Journalism Roots and Early Fascination with Data (0:29) Moving from Finance to Tech and Startups at RPX (2:42) Building Data Infrastructure and Dashboards at Sandana (7:07) What People Mean by the “Sandana Model” and Relationship Focus (10:31) Why Funds Ones and Twos Are Special and How GPs Evolve Over Time (15:09) Why Late-Stage AI and Mega Rounds Don't Replace Early Stage Alpha (19:30) Sponsor Segment: Sidley's Work With AI and Sophisticated Startups (21:16) Tax Optimization and QSBS Considerations for Founders and Investors (24:49) KPIs That Matter: Revenue, Customer Quality, and Go-To-Market (28:40) How Changing Graduation Rates Affect Fund One and Fund Two Diligence (30:24) How to Think About Founder Secondaries vs GP Secondaries (34:54) Portfolio Management, Write-Offs, and the Real Role of Acqui-Hires (37:13) Treating Venture Like Public and Private Equity Segments (Small vs Mega) (40:05) Frustrations With AI Hype, FOMO, and Public Perception of Tech (43:50) Closing Remarks and Reflections on Macro Conversation (45:39) Cendana Capital is a venture fund-of-funds focused on investing in seed-stage venture capital firms and partnering with managers at the earliest stages of company formation. The firm is one of the most active LPs dedicated to the seed ecosystem, with a focus on identifying and supporting differentiated early-stage venture managers. Learn more at www.cendanacapital.com. Sidley Austin LLP is a premier global law firm with a dedicated Venture Funds practice, advising top venture capital firms, institutional investors, and private equity sponsors on fund formation, investment structuring, and regulatory compliance. With deep expertise across private markets, Sidley provides strategic legal counsel to help funds scale effectively. Learn more at sidley.com. Swimming with Allocators is a podcast that dives into the intriguing world of Venture Capital from an LP (Limited Partner) perspective. Hosts Alexa Binns and Earnest Sweat are seasoned professionals who have donned various hats in the VC ecosystem. Each episode, we explore where the future opportunities lie in the VC landscape with insights from top LPs on their investment strategies and industry experts shedding light on emerging trends and technologies.  The information provided on this podcast does not, and is not intended to, constitute legal advice; instead, all information, content, and materials available on this podcast are for general informational purposes only. Learn more about your ad choices. Visit megaphone.fm/adchoices

INTERVIEW: Mikee Carpinter on 'FOUNDATIONS' @ Pearl Diver - afree workshop for music artists + self-managers in the early stage of building a music career by Lily Jane on Radio One 91FM Dunedin

Mike Switzer interviews Sandi Smith, executive director of the Augustine Literacy Project of the Upstate in Mauldin, SC.

A good supplier for precast concrete and steel reinforcement can make all the difference. This Digging Deeper podcast episode features Cam Arnold, general manager of CP&P, a CMC Precast Business, and Robert McClean, vice president of CMC's Fabrication division. We chat about their divisions and how they support concrete contractors every day.

Steffen Szumowski Nuclear Analyst with Vettafi joined Steve Darling from Proactive to discuss the evolving nuclear energy sector, saying today's industry is "hard to recognize" compared with past decades as restarts, plant life extensions, and new reactor construction replace years of shutdowns. Szumowski said the current nuclear revival began before the recent surge in artificial intelligence, describing AI as "gasoline on top of a fire" rather than the original catalyst. He believes the shift was driven primarily by global climate policies following the Paris Agreement, with growing recognition that renewable energy alone cannot provide the reliable, low-carbon baseload electricity needed to meet future demand. The discussion also focused on energy security, with Szumowski pointing to geopolitical events, including the Russia-Ukraine war and tensions involving Iran, as reinforcing the importance of domestic energy independence. He cited France's large nuclear fleet as an example of how nuclear generation has helped reduce exposure to volatile fossil fuel prices. On reactor development, Szumowski highlighted the rapid pace of new construction in China, ongoing projects in the UK and Russia, and continued progress on advanced reactor technologies in the United States. While no new large-scale reactors have yet broken ground in the U.S., he said companies such as Cameco have suggested additional announcements could emerge through U.S. Department of Energy and Department of Commerce initiatives. Looking ahead, Szumowski believes investors have not missed the opportunity, describing the nuclear renaissance as "still just getting started" with additional announcements expected across both large-scale nuclear plants and small modular reactor projects. One ETF to watch is the Range Nuclear Renaissance Index ETF which is designed to track the performance of companies that are involved in the nuclear fuel and energy. #proactiveinvestors #RangeNuclearRenaissanceIndexETF #NuclearEnergy #NuclearRenaissance #Uranium #EnergyTransition #CleanEnergy #SmallModularReactors #AI #PowerGeneration #Investing #EnergySecurity

Amardeep Parmar from Bae HQ welcomes Krishna Visvanathan, CoFounder and Partner at Crane Ventures PartnersAmardeep Parmar:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Krishna Visvanathan: Website:

Startup founder and father to four children with ADHD/ADD, Hagay Levy joins the show today to share his entrepreneurial journey thus far. As a man who also has ADHD himself, he knows much about the unique needs of folks in that community, of which our host, Mai Ling Chan, is also a member. Hagay speaks with Mai Ling about his quest to start Iluria, a new tool for measuring the efficacy of medication for people with ADHD/ADD. They talk about identifying the problem, building a solution to the problem, some of the challenges along the way, what's been accomplished thus far, and where Iluria is headed next.

Joanna Nathan, CEO and co-founder of Prana Surgical, adjunct professor at Rice University and a former MedTech investor who spent years at the J&J MedTech Center for Device Innovation before crossing over into building herself. Her company recently secured FDA clearance for the Prana System, a tissue-sparing platform rethinking how early stage lung cancer is diagnosed and treated.In this episode, Joanna shares the deeply personal story behind her move from investing back into operating, having lost her four year old son in 2021 and wanting proximity to patient impact rather than evaluating innovation from the sidelines. It is an honest and moving conversation about what actually drives someone to take on a decade-long mission.We get into what she learned watching hundreds of pitches from the investor seat, why a no is very often about portfolio construction and timing rather than the quality of your idea, and why a fundraising pitch is a vision document backed by evidence rather than a journal article. Joanna then breaks down the problem Prana is solving, why removing large portions of lung for a tiny early stage nodule is no longer justifiable and how the system is right-sized for the level of risk these smaller lesions present.We also explore the changing face of lung cancer, the rise of never smokers now approaching one in three patients, why the disease is getting younger and more female, the role of mobile screening in rural areas and where AI genuinely helps rather than replaces clinical judgement. Joanna closes with hard-won advice for anyone thinking about founding a company and why community is what carries you through.Timestamps[00:01:38] From Research to Investing to Building: The Path Back to Operating[00:03:33] Why a No From an Investor Is Rarely About Your Idea[00:05:29] Why a Pitch Is a Vision Document Not a Journal Article[00:07:16] The Problem With Early Stage Lung Cancer Surgery Today[00:09:22] The Rise of Never Smokers and a Disease That Is Changing Fast[00:11:03] Why Women Under 50 Now Face Higher Lung Cancer Rates[00:13:18] Getting Creative on Access: Mobile CT Screening in Rural Areas[00:17:21] AI in MedTech: Assisting Clinical Judgement Not Replacing It[00:19:22] How Houston Became an Unlikely MedTech Powerhouse[00:24:06] Who Should Not Become a Founder and the Decade-Long QuestionConnect with Joanna - ⁠linkedin.com/in/joannacnathan/Learn more about Prana Surgical - https://www.pranasurgical.com/Get in touch with Karandeep Badwal - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/in/karandeepbadwal/ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow Karandeep on YouTube - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@KarandeepBadwal⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medical device training courses delivered by Karandeep through Bywater - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.bywater.co.uk/

In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and leadership required to successfully refocus a company on an early-stage pipeline after a lead asset is outlicensed, discontinued or otherwise falls away — an inflection point many biotech and pharma companies face, but few navigate effectively.This episode is presented in partnership with Arvinas. HostJennifer Smith-Parker, Director of Insights, BioSpaceGuestRandy Teel, President and CEO, Arvinas

Welcome to the CanadianSME Small Business Podcast, hosted by Kripa Anand. Today, we break down the operational mechanics of real startup growth and why structural foundations matter more than hype or valuations in 2026. Joining us is Elizabeth Thorsen, Owner and Principal at Elle Thorsen Consulting. Based in Vancouver, Elizabeth has 15+ years of experience guiding tech, climate, and innovation startups toward execution readiness and scalable growth. Key Highlights Fundable vs. Scalable: The difference between raising capital and building a business that lasts. Hype Gap: Why many startups crash after their first major funding round. VC Funding Disparity: The ongoing challenges women-led startups face in venture capital. Ecosystem Gaps: Missing pieces in Canada's startup and accelerator landscape. Responsible AI Growth: How businesses can adopt AI while maintaining sustainability and community impact. Special Thanks to Our Partners: UPS: https://solutions.ups.com/ca-beunstoppable.html?WT.mc_id=BUSMEWA ADP Canada: https://www.adp.ca/en.aspx For more expert insights, visit https://canadiansme.ca/ and subscribe to the CanadianSME Small Business Magazine. Stay innovative, stay informed, and thrive in the digital age! To learn more about how we are supporting the ecosystem, please visit the CanadianSME Small Business Foundation at https://smbfoundation.ca/. Disclaimer: The information shared in this podcast is for general informational purposes only and should not be considered as direct financial or business advice. Always consult with a qualified professional for advice specific to your situation.

Delusions in the Early-Stage Startup Hello, this is Hall T. Martin with the Startup Funding Espresso -- your daily shot of startup funding and investing. The early-stage startup has its own set of delusions founders must overcome. Here's a list of delusions to watch for: Everyone else is a professional but not the founder. The reality is that the founder has the opportunity to build a great business just like anyone else. Financial projections are always wrong. The mistake is believing they are right. The purpose of a financial plan is to start the process of modeling out the business. This will take some time before the financial forecast matches the actual business. The highs and the lows of the business are not forever. The excitement you have now will diminish, and the lows also will come to an end. Success stories heard from other companies typically come from unusual circumstances. The fantastic revenue growth often comes from a phenomenal spend from a highly dilutive fundraise. There's a fear others won't take you seriously. It all comes down to how seriously the founder takes himself and his role. There are rarely situations that are make-or-break for the startup. Few things in the startup experience are existential. In almost all cases, the startup can bounce back. Consider these delusions one may encounter in the startup world and how to overcome them. Thank you for joining us for the Startup Funding Espresso where we help startups and investors connect for funding. Let's go startup something today. _______________________________________________________ For more episodes from Investor Connect, please visit the site at: http://investorconnect.org Check out our other podcasts here: https://investorconnect.org/ For Investors check out: https://tencapital.group/investor-landing/ For Startups check out: https://tencapital.group/company-landing/ For eGuides check out: https://tencapital.group/education/ For upcoming Events, check out https://tencapital.group/events/ For Feedback please contact info@tencapital.group Please follow, share, and leave a review. Music courtesy of Bensound.

Are you ready to stop treating your startup like a side project and start building a scalable business? In this episode, Dr. Michael Burcham shares the hard-earned wisdom of a veteran who has transitioned from a physical therapist to a multi-million dollar private equity investor. We dive deep into the mindset shifts required to go from a day job to a full-time founder, the critical importance of customer discovery, and why most investors won't touch your project until you have skin in the game. Michael breaks down the common mistakes technical founders make and how to navigate the emotional rollercoaster of anxiety and frustration that comes with the territory. You will learn how to differentiate your brand in a noisy market, the power of personal touches in networking, and how to align your vision with what investors are actually looking for. What You'll Learn in This Episode Why most early-stage businesses are still just “projects” ● The biggest mistake founders make before launching ● Why investors care about paying customers more than perfect decks ● How to build awareness without wasting money ● Why failure is part of the entrepreneur DNA ● How to avoid chasing every opportunity ● Why your network can become your biggest growth engine ● How anxiety, insecurity, and frustration show up in business ● What investors see that founders often miss ● Why selling your company can trigger an identity crisis About Justin:   Justin Colby is the host of The Entrepreneur DNA and The Science of Flipping podcasts and a best-selling author. He is a serial entrepreneur and a seasoned real estate investor with over 20 years of experience.   Driven by a passion to help entrepreneurs thrive, Justin created the Entrepreneur DNA community to support business owners in building wealth, systems, and long-term freedom. Through his podcasts, books, education platforms, and hands-on mentorship, he continues to help entrepreneurs scale with clarity and confidence.   Connect with Justin: Instagram: @thejustincolby YouTube: Justin Colby TikTok: @justincolbytsof LinkedIn: Justin Colby About Michael Burcham Dr. Michael Burcham is an investor, author, business strategist, and private equity operator who has spent decades building, scaling, and advising high-growth companies. After starting his career in healthcare, he went on to build and grow multiple companies before transitioning into venture capital and private equity, where he now helps founders navigate growth, fundraising, leadership, and long-term business strategy. He is also the author of multiple books focused on startups, scaling, failure, and investor relationships. Connect with Dr. Michael Burcham: LinkedIn: linkedin.com/in/michaelburcham Instagram: instagram.com/dr.michaelburcham  Website: www.michaelburcham.com Chapters 0:00 Intro and meeting Dr. Michael Burcham 3:15 The journey from physical therapy to private equity 6:30 Why relationships and local ecosystems matter 9:45 The biggest misconception for early stage founders 13:10 Diversifying your offerings and solving customer pain 16:20 The framework for launching a successful venture 19:40 Building awareness and the sales pipeline 23:05 How to differentiate your brand in a noisy market 26:30 The power of handwritten notes and networking 30:00 Projects vs businesses and getting investor attention 33:50 Learning from failure and the importance of grit 37:20 Managing the seven deadly emotions of entrepreneurship 41:00 Identity shifts and the new book Blood Sweat and Equity 44:49 Final thoughts and where to find Michael #entrepreneurship #startupgrowth #venturecapital #businessstrategy #entrepreneurmindset Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the Sports Tech AllStars Podcast, we present Uday Khanna, Co-Founder of 1406 Park Lane Partners and angel investor in sports tech.The conversation explores how a career in M&A transaction advisory led Uday to co-found an early stage investment syndicate focused on sports, emerging sports and wellness, why bringing institutional rigour to pre-seed investing is a genuine edge, and how groups like EBAN Sports are filling a critical gap in the European sports tech funding landscape.Takeaways1406 Park Lane Partners combines M&A advisory, investment banking and private equity experience to bring institutional discipline to early stage sports tech investingThe syndicate's core value proposition is smart capital Emerging sports, data infrastructure and wellness and fitness are the three primary thesis areas for the syndicateMost business angels invest locally by default — cross-border early stage sports tech investment in Europe remains rare and underservedCommunities like EBAN Sports are crucial for connecting sports industry insiders with experienced investors who understand how to scale businessesThe gap between early stage venture and PE is exactly where 1406 Park Lane Partners tries to add value — helping founders understand what institutional readiness looks like before they need itSports tech is still early as an asset class — the deal volume and value has not yet caught up with sectors like healthcare or fintech, but the trajectory is clearPre-seed and early seed is where angel syndicates can have the most impact — founders are more open to collaboration before institutional VCs arriveTo learn more, visit: https://www.linkedin.com/company/1406-park-lane-partnersGet in touch with Uday Khanna at: https://www.linkedin.com/in/upluskHosted by Rohn Malhotra from SportsTechX - Leading source of Investment and Innovation insights in sports.STX Intelligence Hub: sports tech company, investor, and deal database: intelligence.sportstechx.comAs promised, here's your small surprise:Unlock your 30-day growth plan (worth €49) on the SportsTechX Intelligence Hub for free!Simply verify your company details and you get access to 1,500+ investors, programmes, initiatives and events in the sportstech ecosystem.Here's how to get set up and if you'd like a walkthrough of the platform, feel free to book a call here.Download the latest Industry Reports here: https://intelligence.sportstechx.com/reports/gster26Sign Up for the Sports Tech Weekly Newsletter for more news, features & insights on Sports Tech: https://newsletter.sportstechx.com/Chapters00:00 Introduction00:41 What Is 1406 Park Lane Partners and Where Did the Name Come From02:54 From M&A Advisory to Early Stage Sports Tech Investor03:38 Combining M&A, Investment Banking and PE Experience in One Syndicate06:02 Check Size, Deal Stage and Who 1406 Invests In07:54 Smart Capital — Helping Founders Become VC Ready09:19 Thesis Areas: Emerging Sports, Data Infrastructure and Wellness12:23 Pre-Seed and Early Seed as the Sweet Spot for Angel Syndicates13:21 Why Uday Joined EBAN Sports and What It Has Delivered15:25 Using EBAN Sports as a Deal Flow Source and Jury Member16:03 What EBAN Sports Is and How to Get Involved17:44 What PE Experience Brings to Early Stage Investing20:11 What PE Readiness Actually Looks Like and Why It Matters for Founders21:48 The Growing Wave of PE Interest in Sports and Sports Tech22:01 What the Next 12–18 Months Look Like for 1406 Park Lane Partners25:17 Training for a Half Marathon in Madrid and the Tech Used Along the Way27:42 Favourite Sporting MomentStay Connected with SportsTechXSpotify: https://creators.spotify.com/pod/profile/sportstechx/Apple Podcast: https://podcasts.apple.com/in/podcast/the-sports-tech-allstars-podcast/id1271329751LinkedIn: https://www.linkedin.com/company/sportstechxYouTube: https://www.youtube.com/@SportsTechX

Every formulation decision made early in development carries downstream implications for stability, manufacturing, scalability, and analytical strategy. As therapies become more complex and development timelines compress, getting formulation right from the start has never mattered more. In this episode of Life Science Solutions, host Chris Adkins sits down with Kymanox experts Ryan Doxey, VP of Technical Services, and Matt Owen, PhD Associate Director of CMC and Pharmaceutical Sciences. Together, they introduce the newly announced Kymanox Formulation Lab and discuss why having dedicated wet lab space is essential for true IND-enabling formulation development.While Contract Development and Manufacturing Organizations (CDMOs) are built for throughput and execution, they are typically not staffed or equipped to troubleshoot complex scientific issues. This episode explores how applying a "science driving success" approach early on bridges that gap and ensures that your clinical manufacturing timelines stay on track.Topics Include:The CDMO Bottleneck: Why contract manufacturers lack the agility to spend adequate time developing formulations, and how unsolved early issues cause costly delays in Phase 1 and Phase 2 clinical manufacturing.Quality by Design (QbD): Why developing a product merely to meet a Certificate of Analysis (CFA) is insufficient, and the importance of truly understanding your design space to inherently ensure a quality product.Real-World Case Studies: How unknown peaks during forced degradation/leachable studies can derail timelines, and why understanding complex interactions like heat-catalyzed oxidation is crucial before scaling up.Advanced Characterization: Why CDMOs often skip critical tests like permeation and mucus adhesion studies, and how using tools like nasal cast models ensures an intranasal product has adequate residence time and efficacy.Future Trends: The push for biologics and the resurgence of spray-dried formulations to improve global storage conditions, especially as standard injection vehicles struggle to handle the viscosity of high-concentration antibodies.Taking a thoughtful, science-driven approach to early formulation can help reduce risk and avoid costly development delays.

Analyst Clem Chambers explains the market's big shuffle (0:30) Be on the road to diversification (6:15) 25% = natural limit to long-term returns (12:00) Look at simple technicals and financials, be suspicious of words (16:40) Soft spot for ETFs (24:55) Highlighting Neo Performance Materials (31:45)Show Notes:How Much Further Will Gold And Silver Run?Intel Stock: Why The Trump Call Won't FailaNewFNEpisode transcriptsFor full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

AP's Lisa Dwyer reveals a former Cowboys player who took his life had brain damage.

The days of Talent Acquisition operating as a reactive, order-taking engine are officially over. In today's hyper-competitive tech landscape, headcount is no longer a vanity metric for success—quality of hire is everything.In this episode of Hiring on All Cylinders, we sit down with Frankie Greenwell, Early Stage Talent Lead at EQT Group (one of the world's largest private equity and venture firms), to break down the profound evolution of the talent leader role. Drawing from his experience advising 50+ early-stage portfolio companies, Frankie pulls back the curtain on what venture-backed founders are actually looking for in a TA partner today.If you are a talent acquisition executive looking to transcend traditional recruiting boundaries, bridge the credibility gap with the C-suite, and build a world-class hiring infrastructure from seed to pre-IPO, this masterclass is for you.

In today's episode, we welcomed Charles E. Geyer, MD, to discuss recent FDA approvals of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the management of HER2-positive breast cancer. Dr Geyer is a professor of medicine and chief of Malignant Hematology and Medical Oncology in the Department of Medicine at the University of Pittsburgh and the University of Pittsburgh Medical Center Hillman Cancer Center in Pennsylvania.On May 15, 2026, the FDA approved T-DXd for the neoadjuvant treatment of adult patients with HER2-positive stage II or III breast cancer, as determined by an FDA-authorized test, followed by a taxane, trastuzumab (Herceptin), and pertuzumab (Perjeta); the regulatory agency simultaneously approved post-neoadjuvant T-DXd for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment.In our exclusive interview, Dr Geyer discussed the significance of these approvals, key data from the pivotal trials, and how these new indications for T-DXd are shaking up the HER2-positive breast cancer treatment paradigm.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, William Ho, CEO of IN8bio, explains why gamma delta T cells may have an edge against cancer, including solid tumors like glioblastoma. He also offers up a candid and step-by-step look at what it takes to finance an early clinical-stage cell therapy company through a punishing IPO market and a long cash crunch. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

"We're all digesting artificial intelligence" and its future speed capabilities, says Peter Andersen, who believes investor concerns on AI's limitations have investors intrigued in the quantum computing space despite being in "very early stages." He compares the competing quantum technologies and how they play into the space. Peter explains how companies like Rigetti Computing (RGTI), IonQ (IONQ), and Quantum Computing (QUBT) using the tech today will navigate challenges in the space. ======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Big Mike of Advanced Nutrients joins the podcast to discuss the future of cannabis, the importance of building world-class teams, and why industry-wide collaboration may be the key to long-term success. While alcohol and tobacco industries have benefited from unified advocacy and cooperation, Big Mike argues that cannabis remains too fragmented. He shares his vision for the One Plant Alliance, an initiative designed to bring the hemp and cannabis sectors together under a common purpose. According to Big Mike, true passion for the plant means putting collaboration ahead of competition. The conversation also explores Advanced Nutrients' global expansion, with the company now operating in 122 countries and experiencing 53% growth across Europe. Big Mike discusses emerging markets, the challenges and opportunities facing cultivators, and what it takes to scale a cannabis business on a global level. Plus, hear about the company's breakthrough octoploid genetics technology, which is producing 30-50% higher yields and could significantly impact the future of cultivation. Watch now for an in-depth conversation on innovation, leadership, global growth, and the next evolution of the cannabis industry. Chapter: 00:00:01 - Advanced Nutrients Launches Eighth Generation Formula 00:01:23 - Finding and Understanding the Right People 00:03:14 - Taking Full Accountability and Looking Inward 00:04:33 - Building a World-Class Team Through Self-Awareness 00:07:36 - Octoploid Cannabis Genetics Revolution 00:08:53 - Global Cannabis Distribution and Expansion Plans 00:10:26 - Expanding Global Sales and European Growth 00:11:10 - Choosing Your Cannabis Sector and Becoming an Expert00:12:06 - Cannabis Industry Still in Early Stages 00:13:22 - Educating Congress on Cannabis Policy 00:14:14 - Cannabis Industry: A Wonderful Business JourneyWEBSITE: https://cannatechtoday.com/Make sure to follow our other social media platforms to stay up-to-date on all things Cannabis & Tech Today.https://twitter.com/cannatechtodayhttps://www.facebook.com/CannaTechTodayhttps://www.instagram.com/cannatechtoday

Ryan Lee, Senior VP at Direxion, discusses the ongoing AI-driven surge in semiconductor stocks and highlights tools like the SOXL ETF and a Micron (MU)-focused product. He notes the AI cycle is still in its early stages, supporting continued growth across the space. Lee points to broad exposure in SOXL, including AMD Inc. (AMD), Nvidia (NVDA), Marvell (MRVL), Intel (INTC), ASML Holding (ASML), and TSMC (TSM).======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

How did HG Ventures quietly become one of the most active water tech investors on the planet, without even calling itself a water VC?HG Ventures is the corporate venture capital arm of The Heritage Group, a 100-year-old, family-owned Indianapolis conglomerate active in asphalt, quarries, environmental services and specialty chemicals. With $350M in assets, the fund deploys around $50M a year across 41 portfolio companies and 7 sectors, and ranks 5th globally in water tech by deal count despite water being only 18% of its thesis.Ginger Rothrock holds a PhD in chemistry from UNC Chapel Hill, co-founded the NASDAQ-listed pharmaceutical company Liquidia, was promoted to Managing Director of HG Ventures in December 2025, and is a Global Corporate Venturing Rising Star and Kauffman Fellow with deep expertise in industrial water, industrial wastewater treatment, and corporate venture capital in cleantech.

In this episode of the For Construction Pros Digging Deeper podcast, join Joe Cavanaugh, P.E., VP and GM of Geopier, a division of CMC, to discover more about the company and what they can do to ensure construction projects get off the ground on the right foot.

Commentary by Dr. Jian'an Wang.

At the 2026 American Society of Clinical Oncology Annual Meeting, Dr. Jennifer Ligibel, director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living at the Dana-Farber Cancer Institute, presented early results from the Breast Cancer Weight Loss (BWEL) study. The findings showed that among women with early-stage breast cancer, losing weight led to better physical and mental health, and also helped ease fatigue. Listen to the episode to hear Dr. Ligibel explain: the design of the BWEL study why the women in the study had to have hormone receptor-positive, HER2-negative or triple-negative breast cancer the next steps for the study

Origins hosts Nick Chirls (GP, Asylum Ventures) and Beezer Clarkson (LP, Sapphire Partners) react to their conversation with Nicholas Csicsko, a public/private investor at Trinity. They dig into his framing of “cynical optimism” and why it might be the right posture for venture investing, unpack the growing obsolescence risk for SaaS companies from earlier vintages, and cap it off with a live question: if sovereign wealth pulls back from US venture, what breaks first?For a monthly roundup of the latest venture insights, including the newest Origins episodes, subscribe to the OpenLP newsletter – delivered straight to your inbox: https://subscribe.openlp.vcCHAPTERS:00:00 Welcome to Origins00:54 Musicians as Investors01:39 Cynical Optimism Explained02:47 Investor Role Beyond Cheerleading03:11 Steadying Founder Emotions05:59 SaaS Obsolete Before Liquidity07:06 Old SaaS Playbook Breaks08:00 Lovable Growth Reality Check09:01 Creative Destruction Across Portfolios10:17 LP Optimism and Venture Nuance11:26 Ugly Truths About Great InvestorsLearn more about OpenLP: https://openlp.vcLearn more about Asylum Ventures: https://asylum.vcLearn more about Sapphire Partners: https://sapphire.vc

This week on Swimming with Allocators, growth-investor-turned-LP Yuri Lee (TMRS) joins Earnest and Alexa and explains how her global upbringing and love of technology shaped her investing philosophy and belief that talent can come from anywhere. She walks through TMRS's $3B and growing venture/growth mandate, how they split exposure between early-stage and multi-stage funds, and why they are building an aggressive 50/50 funds and co-investment program. Yuri shares what she looks for in emerging managers in clear, differentiated edge in sourcing, picking, or winning; true product–market fit between a manager's edge and fund strategy; and non-consensus, outlier ideas. Throughout, she offers candid advice on how GPs can better pitch institutional LPs, why most decks sound the same, and what it really takes to stand out in a consensus-heavy, AI-dominated market. Also, Chuck Daly of Sidley talks about how emerging VC managers should think proactively about compliance, conflicts of interest, disclosure, and performance/marketing practices under (and aligned with) the Advisers Act and SEC's marketing rule principles. Highlights from this week's conversation include: How a Global Upbringing Shapes an Investor's Worldview (0:13) Consumer Investing and Game Development Experience (2:22) Market Cycles in SaaS and Consumer Narratives (4:19) TMRS Mandate and Building a New Venture Program (6:16) Early Stage Managers and Differentiated, Non-Consensus Portfolios (9:20) What Matters Most at Early Stage vs Growth Stage (12:08) What LPs Really Want to Hear About: Companies and Decisions (14:11) How Pensions and Institutional LPs Run Diligence (17:04) Managing Portfolio Company Synergies and Conflicts (23:56) Marketing Rule Principles, Performance, and Case Studies (26:21) Why TMRS Uses Co-Invests and Target Mix With Funds (30:15) Barbell Approach: Early Stage Funds and Later Stage Co Invests (32:02) Information Gaps for LPs vs GPs and Founder Access (35:55) Consensus Rounds, Party Rounds, and Manager Profiles (38:56) Role of Non-Consensus Managers and Unique Edges (42:09) Rethinking AI Thesis and Value Capture by Model Labs (43:22) Advice For GPs Moving to LP Roles and Building Empathy (45:20) Final Thoughts and Takeaways (47:18) The Texas Municipal Retirement System is a $48+ billion public pension plan serving employees of participating Texas cities. TMRS invests across a diversified portfolio including public equities, fixed income, real assets, and private equity, with venture and growth investments forming an important component of its private markets strategy. Sidley Austin LLP is a premier global law firm with a dedicated Venture Funds practice, advising top venture capital firms, institutional investors, and private equity sponsors on fund formation, investment structuring, and regulatory compliance. With deep expertise across private markets, Sidley provides strategic legal counsel to help funds scale effectively. Learn more at sidley.com. Swimming with Allocators is a podcast that dives into the intriguing world of Venture Capital from an LP (Limited Partner) perspective. Hosts Alexa Binns and Earnest Sweat are seasoned professionals who have donned various hats in the VC ecosystem. Each episode, we explore where the future opportunities lie in the VC landscape with insights from top LPs on their investment strategies and industry experts shedding light on emerging trends and technologies.  The information provided on this podcast does not, and is not intended to, constitute legal advice; instead, all information, content, and materials available on this podcast are for general informational purposes only. Learn more about your ad choices. Visit megaphone.fm/adchoices

Please visit answersincme.com/860/101385133-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Peter A. Fasching, MD; Michael Gnant, MD, FACS; and Cristina Saura Manich, MD, PhD. In this activity, experts in breast cancer discuss new evidence in neoadjuvant and adjuvant care of early disease. Upon completion of this activity, participants should be better able to: Describe multidisciplinary viewpoints on the role that HER2-directed ADCs may play in the (neo)adjuvant setting for HER2-positive early-stage breast cancer; Evaluate evidence for the (neo)adjuvant use of HER2-directed ADCs in the multidisciplinary management of HER2-positive early-stage breast cancer; and Formulate evidence-based multidisciplinary strategies to optimally incorporate (neo)adjuvant HER2-directed ADCs into the treatment paradigm for HER2-positive early-stage breast cancer.

In this episode of In Demand, Asia and Kim dive into product management. They cover problem space versus solution space and why so many founders and product teams build features based on assumptions, customer requests, or competitive pressure without doing the discovery work necessary to understand what users are actually trying to accomplish. This episode is a masterclass on how to avoid building features nobody uses and how to create products that customers genuinely adopt, value, and pay for. Got a question you'd like Asia to unpack on the podcast? Record a voicemail here. Links:  DemandMaven Subscribe to The Work by DemandMaven on Substack The Lean Product Playbook by Dan Olsen Playing to Win: How Strategy Really Works  Continuous Discovery Habits by Theresa Torres Chapters (00:01:00) - Product discovery and idea validation.(00:03:15) - Why understanding the problem deeply creates better product decisions.(00:06:05) - What product discovery actually means in practice.(00:14:40) - Observational research and watching users interact with products.(00:16:15) - User stories versus hypothetical behavior.(00:19:50) - An example of the user stories you might look for on a SaaS reporting function.(00:23:45) - How support tickets can help lead you to the areas you should start working on.(00:29:00) - Castos example: uncovering integration problems through user stories.(00:37:45) - Theresa Torres and the Continuous Discovery approach.(00:44:30) - How discovery creates clearer product strategy and positioning.

Guest Dr. Glenwood Goss discuss JCO article, "Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer" and the implications of minimal residual disease,  results regarding the efficacy of immunotherapy in the adjuvant setting, and the evolving strategies for patient care in lung cancer treatment. LINK TO FULL TRANSCRIPT

We're going to cure cancer in our lifetime." It's a rallying cry at every charity event, every fundraiser, every race. But what does that actually mean?Dr. Sonal Gandhi, a medical oncologist, joins Ditch the Labcoat to break down what most people don't understand: we already cure cancer. All the time. Early stage cancers like breast, colon, and skin cancer caught in time have cure rates approaching 90 to 100 percent.The challenge is stage four cancer. Metastatic disease. Cancer that has spread to other organs. And even there, the conversation is shifting. Cancer is increasingly becoming a chronic illness. People are living longer with it, sometimes dying with it rather than from it, just like they do with heart disease or diabetes.Dr. Gandhi walks through what "curing cancer" really means, how treatment has evolved beyond chemotherapy into targeted therapies and immunotherapy, and why prevention matters. Up to 40 percent of cancers are related to modifiable lifestyle factors: smoking, alcohol, obesity, lack of exercise. But even doing everything right doesn't guarantee you won't get cancer. Age is the number one risk factor, and we can't modify that.She also challenges the guilt people carry when they're diagnosed and reframes the fear around the "C word." Maybe it's time to pull cancer back into the middle with the menu of other chronic illnesses we manage, not cure.If you've ever wondered what "curing cancer" actually means, why some cancers are more treatable than others, or what you can do to reduce your risk, this episode will reframe how you think about one of medicine's most feared diagnoses.If you've ever wondered why so many people have unexplained symptoms, why standard treatments fail them, or what actually works when medicine runs out of answers, this episode will reframe how you see chronic illness.Dr. Sonal Gandhi's LinkedinEpisode Takeaways1. We already cure cancer. Early stage cancers (stage 1 or 2) caught in time have cure rates approaching 90 to 100 percent, depending on the type.2. Cancer is not one disease. It's dozens of diseases with different stages, treatments, and outcomes. We're better at treating some than others.3. Stage four (metastatic) cancer is increasingly becoming a chronic illness. Treatments help people live longer with cancer, sometimes dying with it rather than from it.4. Up to 40 percent of cancers are related to modifiable lifestyle factors: smoking, alcohol, obesity, and lack of exercise. Being a healthy weight matters for cancer prevention.5. Age is the number one risk factor for cancer. Every decade you get older, cells get worse at repairing mistakes. We can't modify aging.6. Only 10 to 20 percent of cancers are due to inherited genes. Most cancers happen because of the complicated interplay between lifestyle, environment, and cellular aging.7. Immunotherapy works by preventing cancer cells from turning off the immune system, but it can cause severe autoimmune side effects that need rapid treatment.8. Whole body scans and experimental blood tests sound appealing, but they often create more harm than good. Screening needs to be done in context with clear downstream action plans.Episode Timestamps03:51 – What Does "Curing Cancer" Actually Mean?08:15 – Early Stage vs. Late Stage Cancer: The Critical Difference12:42 – How Chemotherapy, Targeted Therapy, and Immunotherapy Work18:35 – Prevention: Lifestyle Factors That Reduce Cancer Risk21:50 – Why Immunotherapy Can Cause Severe Side Effects30:48 – Cancer as a Chronic Illness, Not a Death Sentence38:22 – Environmental and Occupational Cancer Risks45:51 – Why Whole Body Scans Aren't the AnswerDISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.   >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.    Disclosures: Ditch The Lab Coat podcast is produced by (soundsdebatable.com) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University.

Vikram Malhotra, managing director, real estate equities at Mizuho, joined the REIT Report to review trends in the industrial/logistics REIT sector. Despite some softness in the first quarter, a new upcycle remains in place, with big box demand playing a key role, he said.Warehouses of over 500,000 square feet have done “very well,” Malhotra said, as companies like Walmart and Amazon adapt to the necessity of quick, last-mile distribution. Mizuho currently estimates overall sector vacancy at 7.5%. That rate is close to peaking, Malhotra said, and then should modestly trend down. “Until we see vacancy trend to about 6%, I think it'll be really hard to see real rent growth…I think we're at least a year away from a very strong market trend.”As for the impact of current global instability, Malhotra noted that “in the very near term, spot demand is strong, but we are monitoring factors where we could see a sign of a pause.”  Instability is likely to strengthen the reshoring trend that has been a theme for the past few years, Malhotra added. Despite the ongoing conflict, the demand for logistics space is expected to reach 150-200 million square feet annually, a significant uptick from previous years.Chapters:00:00 AI Sparks Logistics Upside 00:57 Industrial Outlook 2026 01:44 Big Box Demand Split 02:33 Conflict Impact Check 03:54 Supply Chains And Data Centers 05:54 Markets Supply Risk 2026 07:55 Vacancy And Rent Path 09:07 Warehouse Design Shifts 10:49 Power And Automation Edge 11:59 AI Driven E Commerce Cycle 12:49 Wrap Up And Subscribe

I want you to think about someone in the early phase of coaching, or even someone further along, who needs a reframe and a new perspective in how they're looking at their coaching process. They're asking good questions. They're excited. They're paying attention. They're engaged in what they're doing. And when I hear certain questions around fat loss, I can quickly tell where the disconnect is. The question itself gives insight into how fat loss is being understood, and that understanding drives the decisions and the emotions that follow. It shapes whether you're making choices that move you forward into a stronger, more informed version of yourself, or whether you're stepping back into recognizable patterns that keep you repeating the same old cycle. So today, I want to walk you through some of the most common fat loss questions that came directly from a recent Zoom we hosted inside the SF coaching method for both new and current clients. And more importantly, I want to show you how much those questions actually reveal. Because when you start looking at fat loss through the right lens, everything about your expectations, your timeline, and your decisions begin to shift.   Time Stamps:   (0:42) The Early Stages of Coaching (5:40) Our Added Layer of Support (7:02) Why Isn't The Scale Moving Yet? (11:54) A More Capable System (16:10) Finding Maintenance Calories (18:35) Interpretation ----------  Apply for SF Coaching Method  https://sarahfechter.ac-page.com/sfhq-cc Complimentary Health Content  https://sarahfechter.ac-page.com/Health_Wellness_Community ----------  Follow Me On Instagram - https://www.instagram.com/sarahfechter.ifbbpro/   Check Out My Website - https://www.sarahfechter.com ----------  This Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, other professional health care services, or any professional practice of any kind. Any reliance on the information provided in this Podcast is done at your own risk and Sarah Fechter Fitness LLC expressly disclaims any and all liability or responsibility for any direct, indirect, incidental, special, consequential or other damages arising out of any individual use of, reference to, reliance on, or inability to use, this Podcast or the information presented in this Podcast. All contents and design for this Podcast are owned by Sarah Fechter Fitness LLC. Always consult your professional team before beginning any exercise or nutrition program.

At the University of Nevada, Reno, researchers are combining robotics, artificial intelligence, and agriculture. The early stages of this research give insight into the sheep industry's future.

Closing real estate deals is a multifaceted process that requires meticulous planning and skillful execution. For you to elevate your success rate and achieve more closed deals, it's crucial to pinpoint and effectively address the underlying causes of any challenges you may encounter. In this LIVE coaching episode, Brent Daniels shares invaluable tips on identifying the root issues and paving the way for successfully closing more real estate deals.For more expert advice, make sure to give the TTP Training Program a visit. ---------Show notes:(1:11) Beginning of today's episode(3:30) Understanding Marketing Budgets: Transitioning from Hustle Season to Scaling(4:45) Picking Your Lane: Choosing Between Direct to Seller, Agent Referrals, or Dispositions(6:06) Leveraging Agent Referrals: Using Offers as an Icebreaker to Build a Deal Network(8:20) Becoming a Sniper: Stacking Distress Lists and Targeting "Ugly Houses"(11:45) Case Study: Overcoming Initial Resistance and Identifying Hidden Opportunities(17:11) The Importance of Providing Value by Understanding Local Tax Foreclosure Laws(20:21) Booking an "Appointment from an Appointment" to Ensure Lead Consistency(24:16) Lean Operations: Managing Leads with Low-Cost Tools During the Early Stages(27:50) The Three Seller Factors: Balancing Speed, Convenience, and Price----------Resources:Real SupermarketSkip GenieDeal MachineTo speak with Brent or one of our other expert coaches call (281) 835-4201 or schedule your free discovery call here to learn about our mentorship programs and become part of the TribeGo to Wholesalingincgroup.com to become part of one of the fastest growing Facebook communities in the Wholesaling space. Get all of your burning Wholesaling questions answered, gain access to JV partnerships, and connect with other "success minded" Rhinos in the community.It's 100% free to join. The opportunities in this community  are endless, what are you waiting for?

In this podcast, experts Joyce O'Shaughnessy, MD; Virginia Kaklamani, MD, DSc; and Seth A. Wander, MD, PhD; discuss real-world insights into tailoring adjuvant therapy regimens in hormone receptor–positive/HER2-negative (HR+/HER2–) early breast cancer (eBC).

Cristiano Fontana, founder and CEO of Three Bridges, a Milan-based advisory firm helping early-stage MedTech companies navigate the full journey from innovation to market. With over 25 years in the industry starting in the family warehouse handling surgical drains and prostheses as a teenager, Cristiano has a perspective on this business that very few people can match.In this episode, we kick things off with something a little different: a conversation about dressing well, the discipline behind it and why confidence is as much about how you present yourself as what you know. From there, we get into something both of us have strong opinions on. Cristiano breaks down why the conference ROI is so hard to measure, why ghosting has become an epidemic in the industry and why the real payoff from an event can take three years to materialise. He also delivers one of the most honest assessments you'll hear: that early-stage MedTech is just 3% of the industry and that the 97%, the commercial machine that actually drives revenue, is largely invisible to the innovation bubble.We also explore what a better event model could look like, why trust beats value proposition every single time in a crowded advisory market and what innovators consistently get wrong when they think one conference pitch will change everything.Timestamps[00:00:33] Why Dressing Well Is a Form of Discipline, Not Vanity[00:05:00] From the Family Warehouse to 25 Years in MedTech[00:07:48] The 97% vs 3% Split That Nobody in Early Stage Wants to Hear[00:08:37] What MedTech Conferences Are Getting Wrong[00:09:35] The Ghosting Epidemic and What It Reveals About Human Nature[00:10:14] Why Conference ROI Can Take Three Years to Show Up[00:12:30] You Don't Sell on Value Proposition, You Sell on Trust[00:13:17] The Uncomfortable Truth About So-Called Investors at Events[00:20:42] What a Better, More Targeted Event Model Would Look Like[00:30:41] Final Advice: Fill Your Gaps Fast and Stop Seeing Experts as a CostConnect with Cristiano - ⁠⁠⁠https://www.linkedin.com/in/cristiano-fontana-medtech-businessdevelopment/Learn more about ThreeBridges - ⁠⁠⁠⁠https://www.threebridges.it/Get in touch with Karandeep Badwal - ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/in/karandeepbadwal/ ⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow Karandeep on YouTube - ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@KarandeepBadwal⁠⁠⁠⁠⁠⁠⁠Medical device training courses delivered by Karandeep through Bywater - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.bywater.co.uk/

Paul Hampton, the CEO and one of the founders of investment manager Evonite, talks to Marek Handzel, the editor of Institutional Real Estate Europe about early stage managers. What are the current barriers to entry? How do investors view smaller investment houses? And what can early stage managers offer in this new cycle?

What does it actually mean to have 'early-stage' osteoarthritis, and does catching it sooner really make a difference? On this week's episode of Joint Action, learn more about early-stage knee osteoarthritis, how it's defined, and why the EsSKOA initiative is changing the way we identify and understand the condition in its earliest phases.Dr. Armaghan Mahmoudian is an Assistant Professor of Movement Sciences and Health at the University of West Florida, where she teaches anatomy and physiology, biomechanics, and research methods, and co-directs the biomechanics and motor learning laboratory. As a clinician-scientist, her research focuses on understanding disease mechanisms and their impact on function and quality of life, with a particular interest in personalised medicine and disease prevention in an ageing population.RESOURCESEsSKOA InitiativeJournal article Reframing early-stage symptomatic knee osteoarthritis (EsSKOA): A strategic lens for trial designCONNECT WITH USNaia Health: https://www.naiahealth.com.au/st-leonards-hubJoin one of our trials https://www.osteoarthritisresearch.com.au/current-trialsInstagram: @ProfDavidHunterTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

What if the thing keeping your brand stuck isn't effort, but focus? In this episode, Emma breaks down the subtle yet powerful differences between early-stage brands and those that scale with consistency and revenue. She reveals why doing more isn't the answer, and how prioritizing the right things is what truly drives growth. You'll learn why unclear messaging, lack of systems, and relying on guesswork can quietly stall your progress, even when you're showing up consistently. Emma walks through the four essential priorities that scaling brands get right, and introduces a free Social Media Health Check to help you identify exactly where your brand stands and what to focus on next. If you've been feeling like you're doing all the things but not seeing results, this episode will help you simplify your strategy and move forward with clarity and confidence. Listen in as Emma explains: Why clear positioning attracts the right audience and speeds up conversions How conversion systems turn visibility into consistent revenue growth How to employ strategic restraint to grow faster  And much, much more!   Connect with Ninety Five Media: Check out our website: ninetyfivemedia.co  Follow us on Instagram: instagram.com/ninety.five.media   Grow your brand's social media presence with us:  Tell us about your business goals and explore how our social media management services can help you reach them! ninetyfivemedia.co/stop-scrolling-start-scaling-inquiry  NEW FREEBIE! What if I told you your content isn't converting, your audience isn't engaging, and it feels like too much work - not because you're failing, but because your social media needs a check-up? Take our FREE Social Media Health Check today to: ✅ See where your social media stands today ✅ Identify your growth stage ✅ Discover the next step to level up your results Just because you haven't seen results yet doesn't mean it has to stay that way. We're here to help. Ready to find out how you're doing? Take our free Social Media Health Check: https://form.typeform.com/to/XFQqYq27

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Dan McHugh, head of the investment team at Yosemite, explains the San Francisco VC group's approach to investing in early-stage cancer therapeutics and funding academic research through unrestricted grants. Founded by Reed Jobs, son of Steve Jobs and Laurene Powell Jobs, Yosemite invests across drug modalities and supporting technologies in the oncology space. Dan talks about his path from bioengineering to biotech venture capital, meeting Reed Jobs on Stanford's fencing team, his CEO turn at Tune Therapeutics, and the current fundraising environment for innovative science.   Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Gili Raanan is the Founder of Cyberstarts, one of the best performing venture funds of the last decade. He is famed for being the seed investor in Wiz, Islands and Cyera, leading to multiple 10x+ funds. He has the only remaining monopoly in venture; cyber security in Israel. If it is good, Gili sees it, it is that simple.  AGENDA: 00:00 — Does the Venture Business Even Work Anymore? 05:58 — The Insane Rise of $150M Seed Rounds! 08:58 — Will Mega Funds Ever Actually Return Venture Economics? 11:13 — How Do You Value Companies Growing at Impossible Speeds? 14:50 — The Truth About Growth: Why Most Companies Eventually Plateau 18:50 — Do Margins Still Matter in the Age of AI? 24:32 — How To Make Mega Money in the World of Secondaries 28:11 — What Are Core Misalignments Between GPs and LPs That No One Discusses? 37:57 — Quick Fire: Best Investment, Most Memorable Founder, Investing Icon    

This episode felt especially important to bring back.If you've ever found yourself emotionally attached too quickly, overlooking red flags, or confusing chemistry with compatibility, this conversation is for you.Inside this episode, I walk you through how to:Slow down without losing momentumStay emotionally grounded in the early stagesDate with intention instead of urgencyBuild real safety and discernment from the startIf dating has felt rushed, confusing, or emotionally draining lately, this is a powerful re-listen (or first listen).Ready to stop running from your emotions, rewire your attachment patterns, and embody secure attachment so you can have the kind of relationship where you are seen, heard, and loved, even on your worst days,I invite you to apply for my Private 1:1 Coaching container, Empowered Secure Love.Apply here:

Republicans unveil the most extreme federal voting restrictions proposed in modern history, Tennessee officials are accused of quietly propping up a payday lender's failed sports betting operation, and scholars warn the U.S. may be entering the early stages of genocide against trans Americans.NewsNew GOP anti-voting bill may be the most dangerous attack on voting rights ever How a Tennessee Official Kept Advance Financial's Sports Betting Company AliveExperts Warn U.S. in Early Stages of Genocide Against Trans Americans Follow @PodSaveThePeople on Instagram.